OMER (Omeros Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by OMER officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Peter B Cancelmo | VP, General Counsel | MIXED | — | — |
| 2026-08-28 | ARNOLD C HANISH | Director | MIXED | — | — |
| 2026-08-25 | David J. Borges | VP, Finance & CAO | MIXED | — | — |
| 2026-08-21 | Thomas J. Cable | Director | MIXED | — | — |
| 2026-08-18 | Joseph L Schocken | Director | A | — | — |
| 2026-08-17 | David J. Borges | VP, Finance & CAO | MIXED | — | — |
| 2026-07-24 | David J. Borges | VP, Finance & CAO | A | — | — |
| 2026-07-24 | Gregory A MD Demopulos | Chairman, CEO & President | A | — | — |
| 2026-07-24 | Peter B Cancelmo | VP, General Counsel | A | — | — |
| 2026-06-22 | ARNOLD C HANISH | Director | A | — | — |
| 2026-06-22 | Peter A MD Demopulos | Director | A | — | — |
| 2026-06-22 | Leroy E. MD PhD Hood | Director | A | — | — |
| 2026-06-22 | Rajiv Shah | Director | A | — | — |
| 2026-06-22 | Thomas J. Cable | Director | A | — | — |
| 2026-06-22 | Diana T. Perkinson | Director | A | — | — |
| 2026-06-22 | Thomas F. Bumol | Director | A | — | — |
| 2026-05-27 | Thomas J. Cable | Director | MIXED | — | — |
| 2026-02-20 | Gregory A MD Demopulos | Chairman, CEO & President | MIXED | — | — |
| 2026-01-14 | David J. Borges | VP, Finance & CAO | MIXED | — | — |
| 2025-10-15 | Gregory A MD Demopulos | Chairman, CEO & President | G | — | — |
| 2025-07-01 | David J. Borges | VP, Finance & CAO | A | — | — |
| 2025-07-01 | Diana T. Perkinson | Director | A | — | — |
| 2025-07-01 | Gregory A MD Demopulos | Chairman, CEO & President | A | — | — |
| 2025-07-01 | ARNOLD C HANISH | Director | A | — | — |
| 2025-07-01 | Peter A MD Demopulos | Director | A | — | — |
| 2025-07-01 | Thomas F. Bumol | Director | A | — | — |
| 2025-07-01 | Peter B Cancelmo | VP, General Counsel | A | — | — |
| 2025-07-01 | Thomas J. Cable | Director | A | — | — |
| 2025-07-01 | Leroy E. MD PhD Hood | Director | A | — | — |
| 2025-07-01 | Rajiv Shah | Director | A | — | — |
| 2024-06-07 | Peter A MD Demopulos | Director | A | — | — |
| 2024-06-07 | Thomas J. Cable | Director | A | — | — |
| 2024-06-07 | Rajiv Shah | Director | A | — | — |
| 2024-06-07 | Diana T. Perkinson | Director | A | — | — |
| 2024-06-07 | Leroy E. MD PhD Hood | Director | A | — | — |
| 2024-06-07 | Thomas F. Bumol | Director | A | — | — |
| 2024-06-07 | ARNOLD C HANISH | Director | A | — | — |
| 2024-04-29 | Peter B Cancelmo | VP, General Counsel | A | — | — |
| 2024-04-29 | Gregory A MD Demopulos | Chairman, CEO & President | A | — | — |
| 2024-04-29 | MICHAEL A JACOBSEN | VP, Finance & CAO | A | — | — |
| 2023-11-21 | Gregory A MD Demopulos | Chairman, CEO & President | Buy | — | — |
| 2023-11-17 | Peter A MD Demopulos | Director | Buy | — | — |
| 2023-11-15 | Gregory A MD Demopulos | Chairman, CEO & President | A | — | — |
| 2023-09-27 | Gregory A MD Demopulos | Chairman, CEO & President | A | — | — |
| 2023-09-27 | Peter B Cancelmo | VP, General Counsel | A | — | — |
| 2023-09-27 | MICHAEL A JACOBSEN | VP, Finance & CAO | A | — | — |
| 2023-09-14 | Thomas F. Bumol | Director | A | — | — |
| 2023-06-27 | Thomas F. Bumol | Director | A | — | — |
| 2023-06-27 | Thomas J. Cable | Director | A | — | — |
| 2023-06-27 | ARNOLD C HANISH | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman, CEO & President | 2,126,986 | — |
| — | Director | 493,102 | — |
| — | Director | 372,898 | — |
| — | Director | 217,178 | — |
| — | VP Patent and General Counsel | 210,645 | — |
| — | Director | 74,390 | — |
| — | Director | 42,567 | — |
| — | VP, Finance & CAO | 22,100 | — |
| — | Director | 17,400 | — |
| — | Director | 10,000 | — |
| — | VP, Finance & CAO | 5,906 | — |
| — | VP, General Counsel | 200 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OMER quote page; the site-wide leaderboard is on the insider transactions hub.